Unique ID issued by UMIN | UMIN000014883 |
---|---|
Receipt number | R000017065 |
Scientific Title | Feasibility study of the treatment of the refractory skin ulcer by the punch graft from the Natural gene therapy area in epidermolysis bullosa |
Date of disclosure of the study information | 2014/08/20 |
Last modified on | 2017/02/20 13:10:58 |
Feasibility study of the treatment of the refractory skin ulcer by the punch graft from the Natural gene therapy area in epidermolysis bullosa
Punch graft from natural gene therapy area in epidermolysis bullosa
Feasibility study of the treatment of the refractory skin ulcer by the punch graft from the Natural gene therapy area in epidermolysis bullosa
Punch graft from natural gene therapy area in epidermolysis bullosa
Japan |
epidermolysis bllosa
Dermatology |
Others
YES
In order to evaluate the efficacy and safety of skin transplantation using punch grafts from "natural gene therapy" area in the bullous epidermolysis patients.
Safety,Efficacy
Exploratory
Others
Not applicable
We evaluate the rate of reepithelialization for the 4th week after the last grafting (%)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver | Other |
skin transplantation using punch grafting from natural gene therapy area to refractory ulcer
6 | years-old | <= |
Not applicable |
Male and Female
Patients diagnosed with epidermolysis bullosa (junctional or dystrophic type)and fulfills as follows:
1.Patient aged 6 years old and up.
2.Patient whose responsible gene for epidermolysis bullosa has been identified.
3.Patient with the skin area in which a natural gene therapy occur.
4.Patients with intractable skin ulcers of bigger than 5 cm2 in size which last for more than 2 weeks.
5.Patient who agreed with genetic ecamination of the skin.
6.Patients who agreed with written informed consent after satisfactory explanation.
1.Patient who has participated in other clinical trials in recent 3 months.
2.Patient who is participating or will participate in other clinical trials.
3. Patients with malignancy except skin malignancy.
4.Patients with pregnancy
5.The patient who may suffer an unjust disadvantage by not participating in this research.
6.Other patients who are evaluated not to be suitable for this research
3
1st name | |
Middle name | |
Last name | Yasuyuki Fujita |
Hokkaido University Graduate School of Medicine
Department of Dermatology
North 15 West 7, Kita-ku, Sapporo 060-8638, Japan
011-706-7387
yfujita@med.hokudai.ac.jp
1st name | |
Middle name | |
Last name | Yasuyuki Fujita |
Hokkaido University Graduate School of Medicine
Department of Dermatology
North 15 West 7, Kita-ku, Sapporo 060-8638, Japan
011-706-7387
yfujita@med.hokudai.ac.jp
Hokkaido University Hospital
Department of Dermatology
Hokkaido University Graduate School of Medicine
Self funding
NO
2014 | Year | 08 | Month | 20 | Day |
Unpublished
Completed
2014 | Year | 02 | Month | 03 | Day |
2014 | Year | 09 | Month | 01 | Day |
2014 | Year | 08 | Month | 18 | Day |
2017 | Year | 02 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017065